Navigation Links
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
Date:10/24/2008

lly on tonabersat received placebo and vice versa. The tonabersat dosage was 20mg a day for the first two weeks, increasing to 40mg a day for the subsequent 10 weeks.

In line with previous experience, tonabersat was generally well tolerated by patients.

It is expected that the detailed results of the trial will be published by Professor Olesen's group in a peer-reviewed article in a leading international journal.

Tonabersat is the leading compound in an exciting new class of selective drugs known as neuronal gap junction blockers, which offer the potential to prevent the onset of migraine as a preferred alternative to acute treatment.

Minster is currently conducting the 500 patient TEMPUS trial of tonabersat in prevention of migraine in the US and Canada. This Phase IIb trial is fully enrolled and results are expected in the first quarter of 2009.

"This is the first time for more than 30 years that a drug designed specifically for migraine prevention shows significant efficacy. There is a huge need for better preventives, so these trial results are very encouraging. It is clear that tonabersat has very real potential in the preventive treatment of migraine," said Professor Jes Olesen, the principal investigator in the trial and Director of the Danish Headache Center.

"The very positive results from this Phase II trial in migraine with aura reinforce our confidence in the potential of tonabersat. These results represent a significant advance in our overall program, which we are well funded to deliver, to establish tonabersat as the treatment of choice for prevention of migraine attacks. We look forward to the results of the TEMPUS trial of tonabersat in the wider migraine population, which is on track to report out in Q1 2009," said Paul Sharpe, Minster Pharmaceuticals' Chief Executive Officer.

Notes for editors:

About Minster Pharmaceuticals plc

Minster Pharmaceuticals is a drug development company focus
'/>"/>

SOURCE Minster Pharmaceuticals plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
2. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
3. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
4. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
5. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
6. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
10. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... EMERYVILLE, Calif. , June 19, 2013 /PRNewswire/ ... performance management solutions, introduced the next-generation of its ... solution, which allows health plans to provide their ... their populations, health factors, medical and prescription drug ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... June 19, 2013  It may seem like an odd ... breast cancer. But these were two of the most talked ... Annual Meeting & Expo that just convened in ... this focus by some of the top internal medicine experts ... with new research that can not only save lives, but ...
(Date:6/18/2013)... NEW YORK , June 18, 2013  Intercept ... stage biopharmaceutical company focused on the development and commercialization ... diseases, today announced the pricing of an underwritten public ... a public offering price of $33.01 per share.  In ... to purchase up to an additional 259,500 shares of ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... (Nasdaq: DVAX ) today reported that it had ... subjects as,part of an environmental exposure chamber study that ... are being screened based on a history of,ragweed allergy ... in,the chamber is being used to select those individuals ...
... Demonstrate Continued Safety, Consistently Positive Clinical ... ... presented today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated ... Coronary Stent System at one year, including continued,clinical superiority in ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
(Date:6/19/2013)... June 19, 2013 The deadline ... is this Friday, June 21 at midnight ET. ... programs and innovative people who’ve raised the bar ... visit http://www.minonline.com/ima . , Any consumer and ... title is eligible to enter. Additionally, advertising agencies ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... results of three important studies have been published in ... of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... using artificial neural networks (ANNs) may improve the ability ... Another study in the June Neurosurgery supports ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... 2009 Laboratory market projections.NEWARK, N.J., April 14 ... G-2 Reports indicates that the clinical diagnostic lab ... by 2017. An increase in genetic testing, ... expanded access to healthcare are among the key ...
... Maine, April 14 IDEXX Laboratories, Inc. (Nasdaq: ... 2009 first quarter financial results for Friday, April 24, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... & Spa,Group, Inc. (OTC Bulletin Board: SOKF), a leading operator ... CEO Liu, Tong, CFO Yu, Xia,and corporate secretary Mu, Yan ... earnings results at 9 am EDT on Thursday,April 16, 2009. ... * US/Canada Toll Free Dial-in #: (866) 811 - 8933, ...
... related blindness by almost 35%, study suggests, , , TUESDAY, ... age-related macular degeneration is on the increase, newer treatments ... disease by about 35 percent, new estimates suggest. , ... Disease Control and Prevention, researchers report that as many ...
... Six New Board of Directors Members Also Appointed and ... Bruce R. Korf, MD, PhD, FACMG, of Birmingham, AL ... Medical Genetics (ACMG), the national professional organization for medical ... President Joe Leigh Simpson, MD, FACMG, of Miami, FL ...
... April 14 Continuing a nine-year tradition of putting ... Lines (NYSE: DAL ) employees today presented ... gift of more than 1,250 handmade quilts. Each quilt, ... airline employees and other volunteers on their own time.(Logo: ...
Cached Medicine News:Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 2Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 3Health News:SOKO Fitness & Spa Group, Inc. to hold 2009 Q3 Earnings Call on Apr. 16 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 3Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 2Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 3Health News:Delta Employees Blanket Salt Lake City Medical Center With Warm Gifts 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
... Access immunoassay system is ... benchtop analyzer that performs ... with panels that include ... infectious disease, blood virus, ...
...
Medicine Products: